Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Jennifer H Lin is active.

Publication


Featured researches published by Jennifer H Lin.


Journal of The American College of Nutrition | 2017

Interaction between Nonsteroidal Anti-inflammatory Drugs and Low-fat Dietary Intervention on Colorectal Cancer Incidence; the Women's Health Initiative (WHI) Dietary Modification Trial

Ikuko Kato; Dorothy S. Lane; Catherine Womack; Cathryn H. Bock; Lifang Hou; Jennifer H Lin; Chunyuan Wu; Jennifer Beebe Dimmer; Michael S. Simon

ABSTRACT Background: The Womens Health Initiative (WHI) Dietary Modification (DM) trial did not show that reductions in dietary fat accompanied by increases in vegetable and fruit consumption decrease the incidence of colorectal cancer. Secondary analyses suggested that aspirin use may modify the intervention effects of DM on colorectal cancer development, although a recent reanalysis including the postintervention period confirmed no main effect of the intervention on reducing colorectal cancer incidence Methods: We analyzed data from 48,834 postmenopausal women who were randomized into the low-fat DM (N = 19,540) or comparison (N = 29,294) group for an average 8.1 years and followed for an additional 9.4 years through August 31, 2014. Exposure to specific class(es) or strength(s) of nonsteroidal anti-inflammatory drugs (NSAIDs) was modeled at baseline and as time-dependent use through the 9-year clinic visit. A Cox proportional hazard model was employed to assess the association of the DM, medication use, and their interaction with colorectal cancer events. Results: A total of 906 incident cases of colorectal cancer were identified during the intervention and postintervention periods. By both exposure models, we found that colorectal cancer incidence was not different in the DM from the comparison group among any type of NSAID users. None of the interactions with any category of NSAID use was statistically significant; however there was most modest evidence for an interaction (p = 0.07) with aspirin use at baseline (hazard ratio [HR] = 0.81, 95% confidence interval [CI], 0.60–1.11 for users; HR = 1.12, 95% CI, 0.97–1.30 for nonusers). Strength and duration of aspirin use at baseline did not alter the associations. Conclusion: Extended follow-up of women in the WHI DM trial did not confirm combined protective effects of aspirin and low-fat diet on colorectal cancer risk among the postmenopausal women.


Blood | 2014

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATETM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Jennifer R. Brown; Peter Hillmen; Susan O'Brien; Jaqueline C. Barrientos; Nishitha Reddy; Steven Coutre; Constantine S. Tam; Stephen P. Mulligan; Ulrich Jaeger; Paul M. Barr; Richard R. Furman; Thomas J. Kipps; Florence Cymbalista; Patrick Thornton; Federico Caligaris-Cappio; Julio Delgado; Marco Montillo; Sven DeVos; Carol Moreno; John M. Pagel; Jan A. Burger; Devon Chung; Jennifer H Lin; Linda Gau; Betty Y. Chang; Jesse McGreivy; Danelle F. James; John C. Byrd


Journal of Clinical Oncology | 2013

A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.

John C. Byrd; Jacqueline C. Barrientos; Stephen Devereux; Jennifer R. Brown; Neil E. Kay; Nishitha Reddy; Susan O'Brien; Thomas J. Kipps; Richard R. Furman; Stephen J. Schuster; Adrian Bloor; Devinder Gill; Patrick Thornton; Claire Dearden; Ulrich Jäger; Christine Barker; Jennifer H Lin; Lori Kunkel; Danelle F. James; Peter Hillmen


Journal of Clinical Oncology | 2017

Time to metastasis or death in non-metastatic castrate resistant prostate cancer (nmCRPC) patients by National Comprehensive Cancer Network (NCCN) risk groups.

Brian Macomson; Jennifer H Lin; Ozgur Tunceli; Ajay S. Behl; Chris Pericone; Siddhant Deshmukh; Neal D. Shore


Stroke | 2018

Abstract WMP89: Long-Term All-Cause Healthcare Costs for Stroke Differ by Stroke Severity

Dejan Milentijevic; Jennifer H Lin; Yen-Wen Chen; Deepti Bisht; Emily Kogan; Kathryn Twyman; Mark J. Alberts


Stroke | 2018

Abstract TP311: Initial Stroke Severity is a Significant Predictor of All-Cause Mortality

Mark J. Alberts; Yen-Wen Chen; Jennifer H Lin; Siddhant Deshmukh; Emily Kogan; Kathryn Twyman; Dejan Milentijevic


Journal of the American College of Cardiology | 2018

INITIAL STROKE SEVERITY IS A CRUCIAL PREDICTOR FOR HEMORRHAGIC STROKE- AND ISCHEMIC STROKE-RELATED MORTALITY

Mark J. Alberts; Jennifer H Lin; Yen-Wen Chen; Emily Kogan; Kathryn Twyman; Siddhant Deshmukh; Dejan Milentijevic


Journal of Clinical Oncology | 2018

Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer).

Sophia Li; Zhijie Ding; Jennifer H Lin; Ajay S. Behl; Chris Pericone; Siddhant Deshmukh; Brian Macomson; Neal D. Shore


Journal of Clinical Oncology | 2018

Assessment of health care resource utilization (HRU) in patients with castration-resistant prostate cancer (CRPC).

Sophia Li; Zhijie Ding; Jennifer H Lin; Chris Pericone; Ajay S. Behl; Neal D. Shore


Journal of Clinical Oncology | 2018

Association of prostate-specific antigen (PSA) trajectories with risk for metastasis and mortality in non-metastatic castration-resistant prostate cancer (nmCRPC).

Sophia Li; Zhijie Ding; Jennifer H Lin; Ajay S. Behl; Chris Pericone; Brian Macomson; Neal D. Shore

Collaboration


Dive into the Jennifer H Lin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mark J. Alberts

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Neal D. Shore

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge